Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
Authors:
- Eugenio GalliEGEugenio Galli
- Federica SoràFSFederica Sorà
- Stefan HohausSHStefan Hohaus
- Silvia BellesiSBSilvia Bellesi
- Francesco AutoreFAFrancesco Autore
- Elisabetta MetafuniEMElisabetta Metafuni
- Idanna InnocentiIIIdanna Innocenti
- John MarraJMJohn Marra
- Alberto FresaAFAlberto Fresa
- Maria Assunta LimongielloMLMaria Assunta Limongiello
- Sabrina GiammarcoSGSabrina Giammarco
- Lucia LeccisottiLucia Leccisotti
- 8 March 2022
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (5) , 837-839
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remissionBlood, 2022
- Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphomaBlood Cancer Journal, 2021
- Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?Blood, 2021
- Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaBlood Advances, 2020
- Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicitiesJournal of Clinical Investigation, 2020
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesBlood Advances, 2020
- CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaBlood, 2019
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019Bone Marrow Transplantation, 2019
- Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk LymphomaTransplantation and Cellular Therapy, 2015
- Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphomaBone Marrow Transplantation, 2012